Helen Hobbs - PFIZER DRN Independent Director

PFIZ34
  

BRL 58.94  1.33  2.31%   

  Director
Dr. Helen H. Hobbs, M.D., is an Independent Director of Pfizer Inc., since December 12, 2011. She is Investigator, the Howard Hughes Medical Institute since 2002, Professor of Internal Medicine and Molecular Genetics and Director of the McDermott Center for Human Growth and Development at the University of Texas Southwestern Medical Center. Member of the American Society for Clinical Investigation and the Association of American Physicians. Elected to the National Academy of Medicine in 2004, the American Academy of Arts and Sciences in 2006, and the National Academy of Sciences in 2007. Received both the Clinical Research Prize and Distinguished Scientist Award from the American Heart Association. In 2012, received the inaugural International Society of Atherosclerosis Prize and in 2015, received both the Pearl Meister Greengard Award and the Breakthrough Prize in Life Sciences. In 2016, received the Passano Award and the Gill Award
Age: 65  Director Since 2011      
212 733 2323  https://www.pfizer.com
Hobbs’ background reflects significant achievements in academia and medicine. She has served as a faculty member at the University of Texas Southwestern Medical Center for more than 20 years and is a leading geneticist in metabolism and heart disease, areas in which Pfizer has significant investments and experience. Pfizer benefits from her experience, expertise, achievements and recognition in both medicine and science.

PFIZER DRN Management Efficiency

PFIZER DRN has return on total asset (ROA) of 10.0 % which means that it generated profit of $10.0 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 31.87 %, meaning that it generated $31.87 on every $100 dollars invested by stockholders. PFIZER DRN management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 36.44 B in total debt with debt to equity ratio (D/E) of 0.44, which is about average as compared to similar companies. PFIZER DRN has a current ratio of 1.37, which is within standard range for the sector. Debt can assist PFIZER DRN until it has trouble settling it off, either with new capital or with free cash flow. So, PFIZER DRN's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PFIZER DRN sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PFIZER to invest in growth at high rates of return. When we think about PFIZER DRN's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

DIRECTOR Since

Robert EckertAMGEN DRN
2016
Judith PelhamAMGEN DRN
1995
Fred HassanAMGEN DRN
2015
Brian DrukerAMGEN DRN
2018
Ronald SugarAMGEN DRN
2010
Robert WilliamsAMGEN DRN
2014
Claudio ElyDIMED ON N2
N/A
Frank BiondiAMGEN DRN
2002
Bruno MachadoDIMED ON N2
N/A
Antonio NappDIMED ON N2
N/A
Gregory GarlandAMGEN DRN
2013
Francois CarbonnelAMGEN DRN
2008
Sanders WilliamsAMGEN DRN
2014
Marcel SapirDIMED ON N2
2010
Vance CoffmanAMGEN DRN
2013
Sergio PizzatoDIMED ON N2
N/A
Rebecca HendersonAMGEN DRN
2009
Charles HolleyAMGEN DRN
2017
David BaltimoreAMGEN DRN
1999
Wanda AustinAMGEN DRN
2017
Ellen KullmanAMGEN DRN
2017
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. PFIZER DRN operates under Drug ManufacturersGeneral classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 79000 people. PFIZER DRN (PFIZ34) is traded on Sao Paolo Stock Exchange in Brazil and employs 79,000 people.

PFIZER DRN Leadership Team

Elected by the shareholders, the PFIZER DRN's board of directors comprises two types of representatives: PFIZER DRN inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PFIZER. The board's role is to monitor PFIZER DRN's management team and ensure that shareholders' interests are well served. PFIZER DRN's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PFIZER DRN's outside directors are responsible for providing unbiased perspectives on the board's policies.
John Young, Group President of Global Established Pharma Bus.
Frank DAmelio, CFO and Executive VP of Bus. Operations
Douglas Lankler, Executive Vice President General Counsel
Dawn Rogers, Chief Human Resource Officer, Executive Vice President
Helen Hobbs, Independent Director
Shantanu Narayen, Director
James Smith, Director
Dennis Ausiello, Independent Director
Mikael Dolsten, President - Worldwide Research and Development
Frances Fergusson, Independent Director
Stephen Sanger, Independent Director
Lidia Fonseca, Executive Vice President CTO and Digital Officer
Wyllie Cornwell, Independent Director
Suzanne Johnson, Independent Director
Alexander Mackenzie, Executive Vice President Chief Development Officer
Geno Germano, Group President of Global Innovative Pharma Bus.
Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations
Sally Susman, Executive Vice President - Corporate Affairs
Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply
Freda LewisHall, Executive Vice President Chief Medical Officer
Rady Johnson, Executive Vice President Chief Compliance and Risk Officer
Dan Littman, Director
Ian Read, Chairman, CEO and Chairman of Executive Committee
James Kilts, Independent Director
Don Cornwell, Independent Director
Charles Hill, Executive Vice President - Worldwide Human Resources
Joseph Echevarria, Director
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business
Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply
Angela Hwang, Group President - Pfizer Essential Health
Ronald Blaylock, Independent Director
Kathrin Jansen, Senior Vice President - Vaccine Research & Development
Michael Goettler, Group President - Pfizer Upjohn

PFIZER Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PFIZER DRN a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in PFIZER DRN without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Performance Analysis Now

   

Performance Analysis

Check effects of mean-variance optimization against your current asset allocation
All  Next Launch Module

Currently Active Assets on Macroaxis

Please check Your Equity Center. Note that the PFIZER DRN information on this page should be used as a complementary analysis to other PFIZER DRN's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Other Tools for PFIZER Stock

When running PFIZER DRN price analysis, check to measure PFIZER DRN's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PFIZER DRN is operating at the current time. Most of PFIZER DRN's value examination focuses on studying past and present price action to predict the probability of PFIZER DRN's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move PFIZER DRN's price. Additionally, you may evaluate how the addition of PFIZER DRN to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go